Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study (English)
Free access
- New search for: Wu, Jia-Yi
- New search for: Zhang, Zhi-Bo
- New search for: Zhou, Jian-Yin
- New search for: Ke, Jing-Peng
- New search for: Bai, Yan-Nan
- New search for: Chen, Yu-Feng
- New search for: Wu, Jun-Yi
- New search for: Zhou, Song-Qiang
- New search for: Wang, Shuang-Jia
- New search for: Zeng, Zhen-Xin
- New search for: Li, Yi-Nan
- New search for: Qiu, Fu-Nan
- New search for: Li, Bin
- New search for: Yan, Mao-Lin
- New search for: Wu, Jia-Yi
- New search for: Zhang, Zhi-Bo
- New search for: Zhou, Jian-Yin
- New search for: Ke, Jing-Peng
- New search for: Bai, Yan-Nan
- New search for: Chen, Yu-Feng
- New search for: Wu, Jun-Yi
- New search for: Zhou, Song-Qiang
- New search for: Wang, Shuang-Jia
- New search for: Zeng, Zhen-Xin
- New search for: Li, Yi-Nan
- New search for: Qiu, Fu-Nan
- New search for: Li, Bin
- New search for: Yan, Mao-Lin
In:
Liver Cancer
;
12
, 3
;
229-237
;
2022
- Article (Journal) / Electronic Resource
-
Title:Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study
-
Contributors:Wu, Jia-Yi ( author ) / Zhang, Zhi-Bo ( author ) / Zhou, Jian-Yin ( author ) / Ke, Jing-Peng ( author ) / Bai, Yan-Nan ( author ) / Chen, Yu-Feng ( author ) / Wu, Jun-Yi ( author ) / Zhou, Song-Qiang ( author ) / Wang, Shuang-Jia ( author ) / Zeng, Zhen-Xin ( author )
-
Published in:Liver Cancer ; 12, 3 ; 229-237
-
Publisher:
- New search for: S. Karger AG
-
Place of publication:Basel, Switzerland
-
Publication date:2022-01-01
-
Size:9 pages
-
ISSN:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:English
-
Keywords:
-
Source:
Table of contents – Volume 12, Issue 3
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 189
-
Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular CarcinomaKudo, Masatoshi et al. | 2023
- 198
-
Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic MetastasesDe, Brian / Upadhyay, Rituraj / Liao, Kaiping / Kumala, Tiffany / Shi, Christopher / Dodoo, Grace / Abi Jaoude, Joseph / Corrigan, Kelsey L. / Manzar, Gohar S. / Marqueen, Kathryn E. et al. | 2023
- 209
-
Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter AnalysisHiraoka, Atsushi / Kumada, Takashi / Tada, Toshifumi / Hirooka, Masashi / Kariyama, Kazuya / Tani, Joji / Atsukawa, Masanori / Takaguchi, Koichi / Itobayashi, Ei / Fukunishi, Shinya et al. | 2022
- 218
-
Efficacy of Local Treatment in Lymph Node Metastasis from Hepatocellular CarcinomaLee, Byung min / Choi, Jin-Young / Seong, Jinsil et al. | 2023
- 229
-
Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective StudyWu, Jia-Yi / Zhang, Zhi-Bo / Zhou, Jian-Yin / Ke, Jing-Peng / Bai, Yan-Nan / Chen, Yu-Feng / Wu, Jun-Yi / Zhou, Song-Qiang / Wang, Shuang-Jia / Zeng, Zhen-Xin et al. | 2022
- 238
-
IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III StudyKudo, Masatoshi / Finn, Richard S. / Galle, Peter R. / Zhu, Andrew X. / Ducreux, Michel / Cheng, Ann-Lii / Ikeda, Masafumi / Tsuchiya, Kaoru / Aoki, Ken-ichi / Jia, Jing et al. | 2022
- 251
-
Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular CarcinomaAndo, Yuwa / Kawaoka, Tomokazu / Kosaka, Masanari / Shirane, Yuki / Johira, Yusuke / Miura, Ryoichi / Murakami, Serami / Yano, Shigeki / Amioka, Kei / Naruto, Kensuke et al. | 2022
- 262
-
Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter StudyXu, Bin / Dong, San-Yuan / Bai, Xue-Li / Song, Tian-Qiang / Zhang, Bo-Heng / Zhou, Le-Du / Chen, Yong-Jun / Zeng, Zhi-Ming / Wang, Kui / Zhao, Hai-Tao et al. | 2022
- 277
-
Trends and Disparities in Stage-Specific Incidence of Hepatocellular Carcinoma among US Adults, 2004–2019Shi, Haoting / Huang, Jingxuan / Zhao, Shi / Jin, Yiwen / Cai, Rong / Ran, Jinjun et al. | 2022
- 281
-
Genomic and Immune Features in an Intrahepatic Cholangiocarcinoma Patient with Microsatellite Instability-High Suffered Rapid Acquired Resistance to PD-1 InhibitorCheng, Zhuo / Zeng, Tianmei / Yang, Guang / Liu, Di / Zheng, Zhi / Yuan, Zhengang et al. | 2023
-
Front & Back Matter| 2023